565 results on '"Till, Brian G"'
Search Results
2. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
3. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
4. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
5. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy
6. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
7. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
8. Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).
9. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.
10. Predictors of severe hematotoxicity after CAR T-cell therapy.
11. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study
12. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
13. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
14. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
15. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
16. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
17. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
18. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
19. Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
20. Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
21. T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
22. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic
23. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
24. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
25. 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma
26. Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
27. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
28. CD8+chimeric antigen receptor T cells manufactured in absence of CD4+cells exhibit hypofunctional phenotype
29. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
30. Pembrolizumab with R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy and Safety with Long-Term Follow-Up
31. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
32. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
33. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma
34. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
35. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma
36. Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
37. Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
38. Supplementary Materials and Methods from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
39. Data from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
40. Supplementary Figures 1 through 10 from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
41. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy
42. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
43. Data from Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
44. Table S1 from Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
45. Data from Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
46. Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
47. Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study
48. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
49. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
50. Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.